Electra Therapeutics, Inc.

Nasdaq: ETRA

Day 22 public/RECENT/IPO Sep 18, 2026/Biological Products, (No Diagnostic Substances)

$9.04

▼ 0.10 (-1.09%)

LIVE

updated 15h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionMarket Positioning · Day 8–30

Understand early market positioning and the first institutional moves.

Focus

Institutional activityPrice behaviorVolumeCatalystsFirst major events

NEUTRALFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence50%

CURRENT THESIS INTERPRETED

Electra Therapeutics, Inc. is a newly public clinical-stage biological products company trading at $9.04 with thin fundamental data available due to the absence of 10-Q or 10-K filings. Institutional presence is supported by multiple Schedule 13D/13G filings, alongside regular insider and Form 4 activity since its recent public debut.

Momentum

Price · since IPOLIVE

Yahoo · 16 pts

H $13.92L $9.04Last $9.04

Current ThesisINTERPRETEDLIVE

Why

+High institutional engagement indicated by 3 Schedule 13D/13G filings
+Active insider reporting with 18 insider forms and Form 4 filings on record

Risks

−No 10-Q or 10-K XBRL fundamental data available yet
−High risk profile as a newly public entity under 90 days in the clinical-stage sector
−Slight negative 1-day momentum of -1.09%

Catalysts

→Future reporting of fundamental financial data via 10-Q or 10-K filings
→Subsequent SEC disclosures and clinical milestone updates

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://electra-therapeutics.com

VIEW-ONLY

Visit

Capturing electra-therapeutics.com…

Screenshot of Electra Therapeutics, Inc.'s official website

SNAPSHOT · live view blocked by site (X-Frame-Options: DENY) · source: SEC 424B4

Resolving official website…

Research EnvironmentLIVE

Research environment · $ETRASEC · market · news

18 evidence items|newest evidence 4d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 64/100 recomputed from 4 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Market Positioning.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $9.04 · -1.09% on the day.via Finnhub quoteVERIFIED

4d agoEVIDENCEPrimary Markets Group September 2026 U.S. IPO Updatevia SeekingAlpha · tier 3, cross-check 10d agoEVIDENCE12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionvia Benzinga · tier 3, cross-check 10d agoEVIDENCEOura Shows How Shaky the IPO Market Really Isvia Yahoo · tier 3, cross-check Sep 28, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Sep 28, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Sep 25, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED Sep 23, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED Sep 23, 2026EVIDENCEVERIFIEDForm 4 filed.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-09-28	SCHEDULE 13G	Electra Therapeutics, Inc.	SEC ↗
2026-09-28	SCHEDULE 13G	Electra Therapeutics, Inc.	SEC ↗
2026-09-25	SCHEDULE 13D	Electra Therapeutics, Inc.	SEC ↗
2026-09-23	4	Electra Therapeutics, Inc.	SEC ↗
2026-09-23	4

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics